Epigenetic reprogramming captures billions while rival longevity therapies fade

Risk capital in biotechnology has crystallized a historic wager: billions are flooding toward epigenetic reprogramming companies while other longevity fields atrophy from funding scarcity. NewLimit closed a $435 million Series C led by Founders Fund and compressed its clinical timeline by a decade, announcing human trials for 2025 after identifying a promising candidate that emerged far sooner than anticipated. Retro Biosciences, which moved from first lab to clinical candidate in three years, completed its latest financing round at a $1.8 billion pre-money valuation, with its RTR242 compound advancing to first-in-human dosing in just 15 months from indication selection. This pattern reveals a defining feature of venture capital: the herd effect, where funding gravitates toward hot zones, creating a self-fulfilling cycle that attracts further investment. What stands out is that epigenetic reprogramming has captured this momentum over senolytic therapies—which clear senescent cells, arrived years earlier, and boast a more impressive portfolio of animal data for age-related reversal. Over the next decade we should expect definitive answers about the clinical viability of reprogramming-based therapies, yet the underlying question remains: will this approach truly dominate rejuvenation science, or did capital simply flow toward the most seductive narrative?